Research Report Explores The Attention Deficit Hyperactivity Disorder Therapeutics Market Will Be Valued At By 2019 to 2029

New York City, United States -- Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis. The worldwide effects of the coronavirus sickness 2019 (COVID-19) are now beginning to be felt, and will essentially influence the Healthcare Industry in 2020.

Both, stimulants and non-stimulants are gaining significant demand for the treatment of attention-deficit hyperactivity disorder. ADHD is one of the most common childhood disorders, and is more prevalent in males than females. ADHD is a chronic condition where treatment cannot cure the patient; however, early diagnosis and treatment could mitigate the symptoms.

There are many effective ADHD therapeutics available, such as stimulants, amphetamine, and methylphenidate, which are generally selected by physicians for first medication. Besides, manufacturers are also continuously focusing on the development of new ADHD therapeutics with a diversity of mechanisms and functions.

The global attention-deficit hyperactivity disorder (ADHD) therapeutics market was valued at US$ 19 Bn in 2020, and is expected to witness a CAGR of 7% during the forecast period (2020–2030).

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4222

Companies covered in Attention Deficit Hyperactivity Disorder Therapeutics Market Report

Pfizer Inc.
Eli Lilly and Company
Novartis AG
GlaxoSmithKline PLC
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical Co., Inc.
Johnson & Johnson
UCB S.A.
Purdue Pharma L.P.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4222

Key Takeaways of ADHD Therapeutics Market Study

Stimulants, under drug type, occupied above 86% of the market value share in the attention-deficit hyperactivity disorder therapeutics market in 2019, owing to their increasing adoption by physicians and parents for the treatment of ADHD.
The adults segment, under age group, accounted for the highest market value share in global ADHD therapeutics market, as ADHD disorder is likely to be found more in adults than pediatric and adolescents.
Retail pharmacies hold a major share in the global ADHD therapeutics market, owing to the high availability of ADHD drugs and ease of access.
North America holds a prominent revenue share in the global attention-deficit hyperactivity disorder therapeutics market, due to the presence of established players in the region.

“Growing prevalence of ADHD disorder and increasing preference for cheaper and effective generic ADHD drugs are expected to boost the ADHD therapeutics market over the coming years,” says a PMR analyst.

Introduction of Innovative Drugs: Key Strategy of Leading Manufacturers

Manufacturers of generic drug are focusing on the introduction of cheaper and effective generic ADHD drugs to increase their market share. These generic drugs can cost several times lower than branded drugs, are equally safe, and of good quality and performance.

Therefore, leaders in the global attention-deficit hyperactivity disorder therapeutics market are now looking forward to developing more generic drugs instead of branded ADHD drugs at a high cost. For instance, in March 2019, ANI Pharmaceuticals, Inc. announced the launch of 18mg and 27mg methylphenidate hydrochloride extended-release tablets for the treatment of ADHD.